Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT1 | Q96EB6 | 13/20 | 1.00 |
| ▸ | SIRT2 | Q8IXJ6 | 5/20 | 1.00 |
| ▸ | SIRT3 | Q9NTG7 | 2/20 | 0.68 |
| ▸ | RECQL | P46063 | 1/20 | 0.68 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.62 |
| ▸ | RB1 | P06400 | 4/20 | 0.52 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8241408 | 0.96 | SIRT1 (0.92) | SIRT1SIRT2SIRT3RECQLBRD3 | |
| SCHEMBL3484381 | 0.91 | SIRT1 (1.00) | SIRT1SIRT2SIRT3RECQLBRD3 | |
| SCHEMBL2143575 | 0.87 | SIRT1 (0.77) | SIRT1SIRT2SIRT3RECQLBRD3 | |
| SCHEMBL1874990 | 0.86 | SIRT1 (0.75) | SIRT1SIRT2SIRT3RECQLBRD3 | |
| SCHEMBL10877409 | 0.82 | SIRT1 (0.70) | SIRT1SIRT2SIRT3RECQLBRD3 | |
| SCHEMBL8244015 | 0.81 | SIRT1 (1.00) | SIRT1SIRT2SIRT3RECQLMEN1 | |
| SCHEMBL4165081 | 0.81 | SIRT1 (0.75) | SIRT1SIRT2SIRT3RECQLMEN1 | |
| SCHEMBL1870769 | 0.81 | SIRT1 (1.00) | SIRT1SIRT2SIRT3RECQLMEN1 | |
| SCHEMBL1874310 | 0.81 | SIRT1 (1.00) | SIRT1SIRT2SIRT3RECQLMEN1 | |
| SCHEMBL1275557 | 0.81 | SIRT1 (1.00) | SIRT1SIRT2SIRT3RECQLMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115677672-B | Tetrahydrocarbazole-1-carboxamide derivative and preparation method and application thereof | 厦门大学 | 2024-01-02 | — | — | CN | claimed |
| CN-115677672-A | Tetrahydrocarbazole-1-formamide derivative and preparation method and application thereof | 厦门大学 | 2023-02-03 | — | — | CN | claimed |
| JP-2008509909-A | — | — | 2008-04-03 | — | — | JP | claimed |
| EP-1778252-A2 | NONCARDIOTOXIC PHARMACEUTICAL COMPOUNDS | Barbeau, Donald L. (US) | 2007-05-02 | — | — | EP | claimed |
| WO-2006020573-A2 | NONCARDIOTOXIC PHARMACEUTICAL COMPOUNDS | BARBEAU DONALD L (US) | 2006-02-23 | — | — | WO | claimed |
| US-20060035863-A1 | Noncardiotoxic pharmaceutical compounds | B&G PARTNERS, LLC | 2006-02-16 | — | — | US | claimed |
| CN-115677672-B | Tetrahydrocarbazole-1-carboxamide derivative and preparation method and application thereof | 厦门大学 | 2024-01-02 | — | — | CN | disclosed |
| CN-115677672-B | Tetrahydrocarbazole-1-carboxamide derivative and preparation method and application thereof | 厦门大学 | 2024-01-02 | — | — | CN | disclosed |
| CN-115677672-B | Tetrahydrocarbazole-1-carboxamide derivative and preparation method and application thereof | 厦门大学 | 2024-01-02 | — | — | CN | disclosed |
| US-11591314-B2 | Process for preparing tetrahydrocarbazole carboxamide compound | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-02-28 | — | — | US | disclosed |
| US-11591314-B2 | Process for preparing tetrahydrocarbazole carboxamide compound | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-02-28 | — | — | US | disclosed |
| CN-115677672-A | Tetrahydrocarbazole-1-formamide derivative and preparation method and application thereof | 厦门大学 | 2023-02-03 | — | — | CN | disclosed |
| CN-115677672-A | Tetrahydrocarbazole-1-formamide derivative and preparation method and application thereof | 厦门大学 | 2023-02-03 | — | — | CN | disclosed |
| WO-2005072408-A2 | TREATING A VIRAL DISORDER | ELIXIR PHARMACEUTICALS, INC (US) | 2005-08-11 | — | — | WO | disclosed |
| WO-2005026112-A2 | METHODS OF TREATING A DISORDER | ELIXIR PHARMACEUTICALS, INC. (US) | 2005-03-24 | — | — | WO | disclosed |
| US-6175015-B1 | USEFUL IN THE TREATMENT OF SCHIZOPHRENIA, DEPRESSION, ALZHEIMER'S DISEASE, PARKINSON'S DISEASE AND OTHER DISORDERS THAT RESPOND TO DOPAMINERGIC BLOCKADE, AND FOR TREATING SIDE EFFECTS OF NEUROLEPTIC AGENTS | NEUROGEN CORPORATION | 2001-01-16 | — | — | US | disclosed |
| EP-0923574-A1 | FUSED INDOLECARBOXAMIDES: DOPAMINE RECEPTOR SUBTYPE SPECIFIC LIGANDS | NEUROGEN CORPORATION (US) | 1999-06-23 | — | — | EP | disclosed |
| US-5892041-A | NERVOUS SYTEM AND PSYCHOLOGICAL DISORDERS | NEUROGEN CORPORATION (US) | 1999-04-06 | — | — | US | disclosed |
| WO-1998006717-A9 | FUSED INDOLECARBOXAMIDES: DOPAMINE RECEPTOR SUBTYPE SPECIFIC LIGANDS | — | 1998-07-23 | — | — | WO | disclosed |
| WO-1998006717-A1 | FUSED INDOLECARBOXAMIDES: DOPAMINE RECEPTOR SUBTYPE SPECIFIC LIGANDS | NEUROGEN CORPORATION (US) | 1998-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035863-A1 | Noncardiotoxic pharmaceutical compounds | KCNN3, TNNI3, TNNT2 | SIRT1 4291/4885SIRT2 4734/4885SIRT3 4269/4885 |
| US-11591314-B2 | Process for preparing tetrahydrocarbazole carboxamide compound | CYP2C8, CYP3A7, PARP8 | SIRT1 1020/4885SIRT2 949/4885SIRT3 1001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.